Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis.
about
CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomasTumor site immune markers associated with risk for subsequent basal cell carcinomasMorphometric characteristics of basal cell carcinoma peritumoral stroma varies among basal cell carcinoma subtypes.Presence of ulceration, but not high risk zone location, correlates with unfavorable histopathological subtype in facial basal cell carcinomaSoluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinomaBasal cell carcinoma: stressful life events and the tumor environment.Melanoma update: diagnostic and prognostic factors that can effectively shape and personalize management.Histological subtypes of periocular basal cell carcinoma.Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening.Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing.Clinical significance of IL-2 and IL-10 gene polymorphisms and serum levels in patients with basal-cell carcinoma.Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of sBCC.Dermal changes in superficial basal cell carcinoma, melanoma in situ and actinic keratosis and their implications.Differential expression patterns of metastasis suppressor proteins in basal cell carcinoma.Trends in the incidence of basal cell carcinoma by histopathological subtype.Anatomic location of Basal cell carcinomas may favor certain histologic subtypes.Margin involvement and clinical pattern of basal cell carcinoma with mixed histology.CXCR3 ligands promote expression of functional indoleamine 2,3-dioxygenase in basal cell carcinoma keratinocytes.Analysis of 256 cases of basal cell carcinoma after either one-step or two-step surgery in a Japanese institution.A phase I clinical trial demonstrates that nfP2X7 -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma.Conventional Versus Giant Basal Cell Carcinoma, a Review of 57 Cases: Histologic Differences Contributing to Excessive Growth.
P2860
Q33816432-33089A6C-8926-4EC7-AD11-E000CE781116Q34042944-C5B16C5A-1129-4B97-8673-D7D36EC9E64FQ34190300-B011D6FD-F925-475A-82E0-51C653868F0FQ36465048-37E23751-24A9-4953-A277-AD8FD04BCDC2Q37215888-ECB8B17E-CE40-47A7-8AF4-CF8ACB5262F7Q37471922-E0917665-43C2-4F4A-B19E-902D5BFF3D7AQ37886997-03979C6F-B7A7-4F45-AC97-31DBEE847AA6Q38188596-52099FBE-E85C-4AFB-A64D-FED24F66E33AQ38731383-C27E6A34-595F-4112-93BD-4F880A8435D4Q39158937-634A0BAE-ABD6-4ED7-B4FC-1D8FFC699C36Q41095136-714A6C93-80F6-4C73-B7DA-A83BD27F11BDQ42437852-2F0A6A9E-08EE-4DCA-A781-88025DAE91C3Q42446352-CE474504-06F3-4CC1-9FB4-BAE062A1670BQ42468963-642E9E12-6834-4029-9781-D144B182C6A6Q42476971-9790B977-52DE-476A-A40D-98D0F51CDCAFQ42480006-A24DB0F5-1566-424F-99B5-4344B83E33B4Q42487709-650E5A32-23AB-4675-A8BB-F7E04BC49AE4Q42490694-FABC2F0A-0F43-418B-98F7-55575E1C776CQ42495080-30A79A07-7C03-4C24-9CA6-D4EA2CE63C83Q42505092-5237CFD2-9632-4ABE-8BE1-EDCB253A6FFDQ52564828-BFC517C2-4C49-41F8-87C2-64DADF4CF29C
P2860
Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Basal cell carcinoma progressi ...... ations: a histologic analysis.
@en
Basal cell carcinoma progressi ...... ations: a histologic analysis.
@nl
type
label
Basal cell carcinoma progressi ...... ations: a histologic analysis.
@en
Basal cell carcinoma progressi ...... ations: a histologic analysis.
@nl
prefLabel
Basal cell carcinoma progressi ...... ations: a histologic analysis.
@en
Basal cell carcinoma progressi ...... ations: a histologic analysis.
@nl
P1476
Basal cell carcinoma progressi ...... rations: a histologic analysis
@en
P2093
Michael Mulvaney
Prahbjot Kaur
P304
P356
10.1097/00000372-200608000-00002
P577
2006-08-01T00:00:00Z